Olema Pharmaceuticals, Inc. (OLMA)

NASDAQ • Healthcare

$10.22

-$0.46 (-4.4%)

Market closed

Last close at September 11, 2026 at 20:00 UTC

Open$10.79

Day Range$10.18 - $10.86

Avg. Volume (3M)843K

Market Cap$892.6M

52 Week Range

$6.65$36.26

Next EarningsIn 57 daysNov 9, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$204.5M

EPS (TTM)

-$2.12

ROA (TTM)

-42.04%

Current Ratio

8.86

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-18.6%Q3 2025-$0.51

-11.4%Q4 2025-$0.49

+2.0%Q1 2026-$0.5

0.0%Q2 2026-$0.52

-10.6%Q3 2026-$0.61

Nov 9

in 57 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -10.6%

Olema Pharmaceuticals’ loss per share trailed expectations in the second fiscal quarter of 2026, based on preliminary results reported August 10, 2026, with EPS of -$0.61 coming in below the -$0.55 estimate (difference -$0.06) and down from -$0.51 a year ago. The clinical-stage women’s oncology biotech posted net income of -$63.2 million, a -44.3% year-over-year change versus -$43.8 million in the prior-year period, alongside operating income of -$67.2 million. Cash use remained heavy, with negative operating cash flow of -$45.9 million for the quarter as the company continued advancing its OP-1250 program in breast cancer. Consensus for the next period calls for EPS of -$0.60 on revenue of $1.2 million.

View full earnings history

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on women's oncology. The company develops therapeutic candidates for breast cancer and related hormone-driven disease settings, and it operates as a small-cap clinical-stage business based in healthcare. Olema has been public since its 2020 NASDAQ debut.

Name

Olema Pharmaceuticals, Inc.

CEO

Sean Bohen

Website

www.olema.com

Industry

Healthcare

Year Founded

2006

Employees

150

Today's Snapshot

AI-generated

OLMA closed 4.4% lower at 10.22, while its sector was flat. Citi analyst maintained a Buy rating and a $59 price target for Olema Pharmaceuticals.

Trading Volume

Below 10d avg (806.0K)

753.7K

vs S&P 500 Today

Strong Underperformance

-5.33%

Updated: September 11, 2026 at 20:05 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

OLMA is priced near 10.22 and registers a sell bias driven by predominant weakness across moving averages and momentum measures. Most short- and longer-term averages lie well above the current price and the CCI and momentum readings are negative, while ADX indicates only a weak directional trend. Volatility is relatively elevated with an ATR around 0.59, and although OBV shows accumulation, that volume signal conflicts with the broader technical picture. The classic pivot is above the market, reinforcing resistance. Technical takeaway: Sell — moving-average and momentum deterioration outweigh mixed volume evidence.

All signals